Dulaglutide as a demethylating agent to improve the outcome of breast cancer.

Dulaglutide emerged as a promising therapeutic option for diabetes mellitus Type 2 (DM2). Owing to epigenetic similarities between the pathophysiology of DM2 and breast cancer (BC), we investigated the antitumor effect of dulaglutide. To investigate the effect of dulaglutide, we analyzed the expression of methylated gene promoter regions in BC (, and ).